Page 2450 - Williams Hematology ( PDFDrive )

2421
2420 Index Index 2421

in macrophage activation, 1085–1086, for venous thromboembolism, 2274–2275, comparison with other tyrosine kinase
1085f 2274t, 2275t inhibitors, 1451t
in megakaryopoiesis, 1817, 1821 Dacarbazine. See also ABVD regimen drug interactions, 339t, 1451t
natural killer cells and, 1191 for malignant histiocytic diseases, 1110 for mastocytosis, 977
in neonatal phagocytic function, 107 mechanism of action, 329 pharmacology, 338, 339t, 340–341, 1454
in regulation of inflammation, 286t, Dacetuzumab, for myeloma, 346t resistance to, 319t
287–288 Daclizumab, for pure red cell aplasia, 544 structure, 340f
stem cell factor. See Stem cell factor (SCF) Dacryocytes (teardrop cells), 21f, 473f, 473t, Daunomycin, for acute myelogenous
in transfusion reactions, 2374, 2375 474f leukemia in children, 1409
for vaccine therapy enhancement, 422 Dactylitis, 771 Daunorubicin, 327–328
Cytolytic T cells, 1139 DAF (decay accelerating factor), 572 for acute lymphoblastic leukemia, 1515,
Cytomegalovirus (CMV) infection DAG (diacylglycerol), 935, 1016, 1849 1516
antiphospholipid antibodies and, DAH (diffuse alveolar hemorrhage), 368 for acute myelogenous leukemia, 1395,
2234 DAI (DNA-dependent activator of IRFs), 1395t, 1408
complications, 1266t 302f, 303 for acute promyelocytic leukemia, 1404,
differential diagnosis, 1269 Dalbavancin, 385 1405t
epidemiology, 1261–1262 Dalteparin, for venous thromboembolism, adverse effects, 328, 1519t
after hematopoietic cell transplantation, 2274t DCs. See Dendritic cells (DC)
369–370, 2374 Damaged (“smudge,” “basket”) cells, 23 DC-SIGN (CD-209), 308, 1057t, 1082
in immunocompromised host, 385, Danaparoid, 398 DDAVP. See Desmopressin (DDAVP)
1267–1268 for heparin-induced thrombocytopenia, D-dimer levels
preventive therapy, 389, 1268, 2374 2030, 2031t aging and, 135, 137
T-cell therapy, 409–411, 410f, 411f for unstable angina, 2296 in deep vein thrombosis, 2269
in transplant recipients, 1267–1268 Danazol in disseminated intravascular coagulation,
Cytomegalovirus (CMV) mononucleosis, for autoimmune hemolytic anemia, 839 2206
1266–1268 for immune thrombocytopenia, 2007 in pulmonary embolism, 2271
clinical manifestations, 1263t, 1267 for paroxysmal nocturnal hemoglobinuria, DDT, 517
complications, 1267 579 Dead fetus syndrome, 2211
epidemiology, 1266 D antigen, 2330, 2336 Death domain (DD), 205, 249
history, 1266 DAP (γ-D-glutamyl diaminopimelic acid), Death effector domains (DEDs), 205, 207f
laboratory features, 1267, 1267t 299, 301f Death-inducing signaling complex (DISC),
treatment, 1269 DAP12, 1190 205
Cytopenias, 1277, 1610 DAPK, 1528 DEC205, 310
Cytoplasmic antineutrophil cytoplasmic Dapsone DEC205/CD205 lectin receptor, 308, 310
antibody (cANCA), 1013 adverse effects, 2007 Decay accelerating factor (DAF), 572
Cytoplasmic granules, 1145, 1511, 1511f G6PD deficiency and, 708t, 712, 1252 Decitabine, 322
Cytoreductive therapy, for essential for immune thrombocytopenia, 2007 for acute myelogenous leukemia, 1403
thrombocythemia, 1313–1314, prophylactic, 389 mechanism of action, 239, 1360–1361
1313t toxic methemoglobinemia and, 790t, 793 for myelodysplastic syndromes, 239, 336,
Cytosine arabinoside. See Cytarabine (ara-C) Dapsone-trimethoprim, 386 1360–1361
Cytosine methylation, 162 Daptomycin, 384, 385, 388t for sickle cell disease, 774t, 775
Cytotoxicity disorders. See Darapladib, for atherosclerosis, 2286 Dectin-1
Immunodeficiency diseases, Daratumumab, for myeloma, 345, 345f, 346t, in fungal infection susceptibility, 1057t,
cytotoxicity disorders 1754–1755 1230
Cytotoxic T cells. See CD8+ T cells (cytotoxic Darbepoetin, 554. See also Erythropoiesis- in innate immunity, 295, 1084
T lymphocytes, CTLs) stimulating agents (ESAs) toll-like receptors and, 1054, 1055f, 1057t
Cytotoxic T-lymphocyte antigen (CTLA)-4, DARC (Duffy antigen receptor for Dedicator of cytokinesis 8 (DOCK)
424, 1184, 1224 chemokines), 285 deficiency, 1215t, 1221–1222
Darling-Roughton effect, 795 DEDs (death effector domains), 205, 207f
D Dasatinib, 338–341 Deep vein thrombosis (DVT).
D6, 285 for acute lymphoblastic leukemia, 1518 See also Venous thrombosis/
D409H, 1123, 1123t for acute myelogenous leukemia, 1403 thromboembolism
Dabigatran, 399, 401 adverse effects, 339t, 341, 1203, 1451t, in antiphospholipid syndrome, 2238
adverse effects, 2275t 1453–1454 complications, 2269
clinical studies, 400t for chronic myelogenous leukemia, 176, definition and epidemiology, 2267
mechanism of action, 1919 339t, 1451t, 1453–1454, 1457, 1466 differential diagnosis, 2269, 2270f

Kaushansky_index_p2393-2506.indd 2421 9/21/15 3:21 PM